Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Zorevunersen sodium by Stoke Therapeutics for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy): Likelihood of Approval
Zorevunersen sodium is under clinical development by Stoke Therapeutics and currently in Phase II for Dravet Syndrome (Severe Myoclonic Epilepsy...
Data Insights
Risk adjusted net present value: What is the current valuation of Stoke Therapeutics's Zorevunersen sodium?
Zorevunersen sodium is an antisense oligonucleotide commercialized by Stoke Therapeutics, with a leading Phase II program in Dravet Syndrome (Severe...